Psilocybine — Drug Intelligence | 13 EU Trials

Filter these 13 trials by condition, phase, country and more.

Open in Search →

13 Registered trials

4 Recruiting

6 Completed trials

9 Sponsors

11 Countries

Phase III

Phase II

Phase III: 2 Phase II: 11

Oversight events:

1 temporary halt 3 corrective measures across 2 trials

View oversight register →

Indications tested

Alcohol use disorder 2 Major depression 1 Fibromyalgia 1 Depressive symptom 1 Depression 1 Psychogenic seizure 1

Sponsors using this IMP

Centre Hospitalier Universitaire De Nantes 4 Narodni Ustav Dusevniho Zdravi 2 Compass Pathfinder Limited 1 Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau 1 LKH Graz II 1 Psyon s.r.o. 1 Region Stockholm – SLSO 1 Universitair Medisch Centrum Groningen 1 Universiteit Maastricht 1

All trials

13 total

Psilocybin in treatment-resistant depression Pending

2024-518654-16-01 Phase II 1 country LKH Graz II
Antidepressant effects of psilocybin without the psychedelic serotonin experience: A dimensional approach using functional neuroimaging. Pending

2025-521690-14-00 Phase II 1 country Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau
ERPPAD - Efficacy in Relapse Prevention: Psilocybin in Alcohol use disorder with Depressive symptoms Recruiting

2025-525069-65-00 Phase III 1 country Centre Hospitalier Universitaire De Nimes
PsyPal; Psilocybin Therapy for Psychological Distress in Palliative Patients Recruiting

2023-510488-36-01 Phase II 4 countries Universitair Medisch Centrum Groningen
Regression of Atherosclerosis induced by liFe chAnging Experience with psiLocybin Recruiting

2024-517902-27-00 Phase II 1 country Psyon s.r.o.
Psilocybin - a strategy of rapid antidepressant response in depression comorbid with cancer,a randomized double-blind study with the possib… Recruiting

2024-517747-31-00 Phase II 1 country Narodni Ustav Dusevniho Zdravi
Het effect van psilocybine op pijn bij fibromyalgiepatiënten: een multicenter trial Ended

2024-516890-63-00 Phase II 1 country Universiteit Maastricht
Antidepressant effects of psilocybin in pharmaco-resistant depression Ended

2024-515899-13-00 Phase II 1 country Narodni Ustav Dusevniho Zdravi
Evaluation of the effect of a single dose of psilocybin on neural correlates of cognitive control in patients with CNEP (psychogenic nonepil… Ended

2023-509679-17-00 Phase II 1 country Centre Hospitalier Universitaire De Nimes
A Phase III study to investigate two initial administrations of COMP360 in treatment-resistant depression Ended

2023-505268-12-00 Phase III 9 countries Compass Pathfinder Limited
CAPSI - Cancer related major depression treated with a single dose of psilocybin - a multicenter randomized placebo controlled double blind … Halted

2023-505532-35-00 Phase II 1 country Region Stockholm – SLSO
Effect of psilocybin on the positive valence system in treatment-resistant depression: a pilot clinical neuroimaging study Ended

2022-501092-11-00 Phase II 1 country Centre Hospitalier Universitaire De Nimes
Psilocybin in alcohol use disorder with comorbid depression - Randomized double-blind controlled pilot study. Ended

2023-506647-42-00 Phase II 1 country Centre Hospitalier Universitaire De Nimes

Showing 1–13 of 13 trials

← All drugs A–Z